Recognition of an Impairment Loss on Investment Securities (Extraordinary Loss) and Revision of the Earnings Forecast
NIPPON CHEMIPHAR CO.,LTD. (the company; the earnings forecast is on a consolidated basis for the group)
Held securities classified as “other securities” whose fair market value has declined significantly, and core products and new drugs in the pharmaceutical business
The fair market value of held securities classified as “other securities” declined significantly. The earnings forecast revision is due to adjustments to the timing of certain transactions involving core products and new drugs, as well as foreign exchange gains arising from fluctuations in foreign exchange rates, among other factors.
¥163 million (impairment loss on investment securities and extraordinary loss)
Fiscal year ending March 2026 (1 April 2025 to 31 March 2026)
Revised. Net sales: from ¥33,500 million to ¥33,090 million (change of ¥409 million, change rate of -1.2%); operating income: from ¥300 million to ¥179 million (-¥120 million, -40.1%); ordinary income: from ¥100 million to ¥227 million (¥127 million, 128.0%); net income attributable to owners of the parent: from ¥150 million to ¥198 million (¥48 million, 32.0%); basic earnings per share: from ¥41.51 to ¥54.81.
| Item | Details |
|---|---|
| Event name | Recognition of an Impairment Loss on Investment Securities (Extraordinary Loss) and Revision of the Earnings Forecast |
| Date of occurrence | Fiscal year ending March 2026 (1 April 2025 to 31 March 2026). The specific date of occurrence is Not disclosed |
| Subject Entity | NIPPON CHEMIPHAR CO.,LTD. (the company; the earnings forecast is on a consolidated basis for the group) |
| Target Locations / Products | Held securities classified as “other securities” whose fair market value has declined significantly, and core products and new drugs in the pharmaceutical business |
| Cause | The fair market value of held securities classified as “other securities” declined significantly. The earnings forecast revision is due to adjustments to the timing of certain transactions involving core products and new drugs, as well as foreign exchange gains arising from fluctuations in foreign exchange rates, among other factors. |
| Amount of Impact on Business Performance | ¥163 million (impairment loss on investment securities and extraordinary loss) |
| Accounting period in which recognized | Fiscal year ending March 2026 (1 April 2025 to 31 March 2026) |
| Impact on Earnings Forecast | Revised. Net sales: from ¥33,500 million to ¥33,090 million (change of ¥409 million, change rate of -1.2%); operating income: from ¥300 million to ¥179 million (-¥120 million, -40.1%); ordinary income: from ¥100 million to ¥227 million (¥127 million, 128.0%); net income attributable to owners of the parent: from ¥150 million to ¥198 million (¥48 million, 32.0%); basic earnings per share: from ¥41.51 to ¥54.81. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Impairment accounting will be applied to held securities whose fair market value has declined significantly. Regarding the earnings forecast revision, net sales and operating income are expected to fall due to adjustments to the timing of certain transactions involving core products and new drugs in the pharmaceutical business, while ordinary income is expected to rise due to foreign exchange gains on foreign-currency-denominated assets and liabilities, among other factors.